US2011038898A1PendingUtilityA1

Dissolution properties of drug products containing olmesartan medoxomil

56
Assignee: YADA SHUICHIPriority: Mar 13, 2008Filed: Mar 2, 2009Published: Feb 17, 2011
Est. expiryMar 13, 2028(~1.7 yrs left)· nominal 20-yr term from priority
Inventors:Shuichi YadaHideki YanoTsuyoshi NagaikeMisato Yokoi
A61K 47/02A61P 43/00A61P 9/12A61K 31/4422A61K 9/2018A61P 9/00A61K 31/44A61K 31/4178A61K 9/2059A61K 31/4418A61K 31/549A61K 9/2054A61K 31/54A61K 9/2009
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine by using said composition is also provided.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition containing (A) olmesartan medoxomil and (B) amlodipine as active ingredients and (C) a calcium-containing excipient. 
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein component (C) is one or more types of compounds selected from carmellose calcium, calcium silicate, calcium hydrogen phosphate, calcium carbonate, calcium sulfate dihydrate, calcium ascorbate, calcium chloride, and calcium stearate. 
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein component (C) is carmellose calcium. 
     
     
         4 . A pharmaceutical composition according to any of  claims 1 - 3 , wherein the pharmaceutical composition is formulated as a single formulation. 
     
     
         5 . A pharmaceutical composition according to  claim 4 , wherein the drug product is a solid dosage form. 
     
     
         6 . A pharmaceutical composition according to  claim 4 , wherein the drug product is a powder, fine granules, a granule, a capsule, or a tablet. 
     
     
         7 . A pharmaceutical composition according to  claim 4 , wherein the drug product is a tablet. 
     
     
         8 . A pharmaceutical composition according to  claim 1  which is coated. 
     
     
         9 . A pharmaceutical composition according to  claim 8 , wherein component (C) is included in the coating. 
     
     
         10 . A pharmaceutical composition according to  claim 1  which further includes hydrochlorothiazide as an active component. 
     
     
         11 . A pharmaceutical composition according to  claim 1  for treating or preventing hypertension. 
     
     
         12 . A method of improving the dissolution properties of olmesartan medoxomil using a pharmaceutical composition according to  claim 1 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.